dc.contributor.author | Berenguer, Juan | |
dc.contributor.author | Calleja Panero, José Luis | |
dc.contributor.author | Montes, María Luisa | |
dc.contributor.author | Gil, Ángela | |
dc.contributor.author | Moreno, Ana | |
dc.contributor.author | Bañares, Rafael | |
dc.contributor.author | Aldámiz-Echevarría, Teresa | |
dc.contributor.author | Albillos, Agustín | |
dc.contributor.author | Téllez, María Jesús | |
dc.contributor.author | Olveira, Antonio | |
dc.contributor.author | Domínguez, Lourdes | |
dc.contributor.author | Fernández, Inmaculada | |
dc.contributor.author | García-Samaniego, Javier | |
dc.contributor.author | Polo, Benjamín A. | |
dc.contributor.author | Álvarez, Beatriz | |
dc.contributor.author | Ryan, Pablo | |
dc.contributor.author | Barrio, José | |
dc.contributor.author | Devesa, María J. | |
dc.contributor.author | Benítez, Laura | |
dc.contributor.author | Santos Gil, Ignacio de los | |
dc.contributor.author | Buey, Luisa García | |
dc.contributor.author | Sanz, José | |
dc.contributor.author | Poves, Elvira | |
dc.contributor.author | Losa, Juan E. | |
dc.contributor.author | Fernández-Rodríguez, Conrado | |
dc.contributor.author | Jarrín, Inmaculada | |
dc.contributor.author | Calvo, María J. | |
dc.contributor.author | González García, Juan Julián | |
dc.contributor.other | UAM. Departamento de Medicina | es_ES |
dc.contributor.other | Instituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ) | es_ES |
dc.date.accessioned | 2019-11-05T18:12:16Z | |
dc.date.available | 2019-11-05T18:12:16Z | |
dc.date.issued | 2019-05-01 | |
dc.identifier.citation | Open Forum Infectious Diseases 6.5 (2019): 1-10 | en_US |
dc.identifier.issn | 2328-8957 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10486/689124 | |
dc.description.abstract | The efficacy of licensed direct-acting antiviral (DAA) regimens is assumed to be the same for hepatitis C virus (HCV)–monoinfected patients (HCV-Mono) and HIV/HCV-coinfected patients (HCV-Co). However, the high sustained viral response (SVR) rates of DAA regimens and the small number of HIV-infected patients included in registration trials have made it difficult to identify predictors of treatment failure, including the presence of HIV. Methods. We compared treatment outcomes for ledipasvir/sofosbuvir (LDV/SOF) against HCV G1 in treatment-naïve HCV-Mono and HCV-Co without cirrhosis in a prospective registry of individuals receiving DAAs for HCV. Results. Up to September 2017, a total of 17 269 patients were registered, and 1358 patients (1055 HCV-Mono/303 HCV-Co) met the inclusion criteria. Significant differences between HCV-Mono and HCV-Co were observed for age, gender, and G1 subtype distribution. Among HCV-Co, 99.0% were receiving antiretroviral therapy. SVR rates for LDV/SOF at 8 weeks did not differ significantly between HCV-Mono and HCV-Co (96.9% vs 94.0%; P = .199). However, the SVR rate for LDV/SOF at 12 weeks was significantly higher for HCV-Mono than HCV-Co (97.2% vs 91.8%; P = .001). A multivariable logistic regression model including age, sex, liver stiffness, G1 subtype, HCV-RNA, HIV, and treatment duration showed the factors associated with treatment failure to be male sex (adjusted odds ratio [aOR], 2.49; 95% confidence interval [CI], 1.27–4.91; P = .008) and HIV infection (aOR, 2.23; 95% CI, 1.13–4.38; P = .020). Conclusions. The results of this large prospective study analyzing outcomes for LDV/SOF against HCV G1 in treatment-naïve noncirrhotic patients suggest that HIV infection is a predictor of treatment failure in patients with chronic hepatitis C. | en_US |
dc.description.sponsorship | This work was supported by the Spanish AIDS
Research Network (RD16/0025/0017), which is included in the Spanish
I+D+I Plan and is co-financed by ISCIII-Subdirección General de
Evaluacion and European Funding for Regional Development (FEDER),
and the Fondo de Investigación de Sanidad en España (FIS)/Instituto de
Salud Carlos III (Spanish Health Research Funds; PI17/00657). | en_US |
dc.format.extent | 10 pag. | es_ES |
dc.format.mimetype | application/pdf | en |
dc.language.iso | eng | en |
dc.publisher | Oxford University Press on behalf of Infectious Diseases Society of America | en_US |
dc.relation.ispartof | Open Forum Infectious Diseases | en_US |
dc.rights | © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. Background. | en_US |
dc.subject.other | Antiviral agents/administration & dosage/*therapeutic use | en_US |
dc.subject.other | DAA | en_US |
dc.subject.other | Hepatitis C, chronic/*complications/*drug therapy | en_US |
dc.subject.other | HIV infections/*complications | en_US |
dc.subject.other | Sustained virologic response | en_US |
dc.title | HIV coinfection predicts failure of ledipasvir/sofosbuvir in treatment-naïve noncirrhotic patients with HCV genotype | en_US |
dc.type | article | en |
dc.subject.eciencia | Medicina | es_ES |
dc.relation.publisherversion | https://doi.org/0.1093/ofid/ofz214 | es_ES |
dc.identifier.doi | 10.1093/ofid/ofz214 | es_ES |
dc.identifier.publicationfirstpage | 1 | es_ES |
dc.identifier.publicationissue | 5 | es_ES |
dc.identifier.publicationlastpage | 10 | es_ES |
dc.identifier.publicationvolume | 6 | es_ES |
dc.relation.projectID | Gobierno de España. RD16/0025/0017 | es_ES |
dc.relation.projectID | Gobierno de España. PI17/00657 | es_ES |
dc.type.version | info:eu-repo/semantics/publishedVersion | en |
dc.rights.cc | Reconocimiento – NoComercial – SinObraDerivada | es_ES |
dc.rights.accessRights | openAccess | en |
dc.authorUAM | Calleja Panero, José Luis (101541) | |
dc.authorUAM | González García, Juan Julián (258399) | |
dc.facultadUAM | Facultad de Medicina | |
dc.institutoUAM | Instituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ) | |